Nanotherapeutics Overcoming the Blood-Brain Barrier for Glioblastoma Treatment

• Main Authors: Lin Tang (Author), Yicheng Feng (Author), Sai Gao (Author), Qingchun Mu (Author), Chaoyong Liu (Author)
• Formato: Livro
• Publicado em: Frontiers Media S.A., 2021-11-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Glioblastoma (GBM) is the most common malignant primary brain tumor with a poor prognosis. The current standard treatment regimen represented by temozolomide/radiotherapy has an average survival time of 14.6 months, while the 5-year survival rate is still less than 5%. New therapeutics are still hig...